Grifols (ES:GRF) has released an update.
Grifols, a leading global healthcare company, has reported a strong financial performance for the first half of 2024, with a 7.5% increase in revenues to 3.444 billion euros and a positive net profit turnaround to 36 million euros from the previous year’s loss. The company saw substantial growth in its immunoglobulin franchise and albumin sales, particularly in China, and achieved a reduction in leverage ratio to 5.5x. Grifols confirms its 2024 forecasts, underpinned by strategic alliances and efficiency initiatives.
For further insights into ES:GRF stock, check out TipRanks’ Stock Analysis page.
